Trials / Completed
CompletedNCT01133457
Bioequivalence Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition
Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg and Merck & Co., Propecia in Healthy Adult Males Under Fed Condition.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Dr. Reddy's Laboratories Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study was to compare the single-dose relative bioavailability of Dr. Reddy's Laboratories, Ltd. and Merck \& Co. (Propecia®) 1 mg finasteride tablets under fed conditions following administration of a 3 mg dose.
Detailed description
Detailed Description : The study was conducted as an open-label, randomized, single-dose, 2-way crossover, relative bioavailability study performed on 24 healthy adult male volunteers and 2 alternates. A total of 24 subjects completed the clinical phase of the study. In each period, subjects were housed from the evening before dosing until after the 36-hour blood draw. Single oral 3 mg doses were separated by a washout period of 7 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Finasteride | Finasteride tablets 1 mg |
Timeline
- Start date
- 2002-04-01
- Primary completion
- 2002-05-01
- Completion
- 2002-05-01
- First posted
- 2010-05-28
- Last updated
- 2010-05-28
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01133457. Inclusion in this directory is not an endorsement.